Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi- specific monoclonal antibody

International Journal of Cancer

Volumn 73, Issue 2, 1997, Pages 211-219

  Lamers, Cor H J ^a   Bolhuis, Reinder L H ^a   Warnaar, Sven O ^b   Stoter, Gerrit ^a   Gratama, Jan W ^a,c  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b Centocor Europe B V   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; ANTIBODY SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; HUMAN; IMMUNOMODULATION; OVARY CANCER; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; ASCITIC FLUID; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INFUSIONS, PARENTERAL; LEUKAPHERESIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; OVARIAN NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0030796406     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971009)73:2<211::AID-IJC9>3.0.CO;2-Z     Document Type: Article

References (21)

1. BÉNARD, J., DA SILVA, J., DE BLOIS, M.C., BOYER, P., DUVILLAND, P., CHIRIC, E. and Riou, G., Characterization of a human ovarian adenocarcinoma line. IGROV1, in tissue culture and in nude mice. Cancer Res., 45, 4970-4979 (1985).
2. BLANK-VOORTHUIS, C.J.A.C., BRAAKMAN, E., RONTELTAP, C.P.M., TILLY, B.C., STURM, E., WARNAAR, S.O. and BOLHUIS, R.L.H., Clustered CD3/TCR complexes do not transduce activation signals after bi-specific-monoclonalantibody-triggered lysis by cytotoxic T lymphocytes via CD3. J. Immunol., 151, 441-444 (1993).
3. - cloned T lymphocytes requires the involvement of the T3 antigen for signal transducfion. Cell. Immunol., 93, 46-57 (1985).
4. BUCKMAN, R. and 13 OTHERS. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast, using radioiodinated monoclonal antibody 2G3. Gynecol. Oncol., 47, 102-109 (1992).
5. CANEVARI, S. and 17 OTHERS, Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T-lymphocytes re-targeted by a bi-specific monoclonal antibody: clinical proof of concept. J. nat. Cancer Inst., 87, 1463-1469 (1995).
6. GRATAMA, J.W., SCHMITZ, P.I.M., GOEY, S.H., LAMERS, C.H.J., STOTER, G. and BOLHUIS, R.L.H., Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, INFα and autologous IL-2 activated lymphocytes). Int. J. Cancer, 65, 152-160 (1996).
7. IOANNIDES, C.G., PLATSOUCAS, C.D., RASHED, S., WHARTON, J.T., EDWARDS, C.L. and FREEDMAN, R.S., Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res., 51, 4257-4265 (1991).
8. KROESEN, B.J., BUTER, J., SLEIJFER, D.T., JANSSEN, R.A.J., VAN DER GRAAF, W.T.A., THE, T.H., DE LEU, L. and MULDER, N.H., Phase-1 study of intravenously applied bi-specific antibody in renal-cell-cancer patients receiving subcutaneous interieukin-2. Brit. J. Cancer, 70, 652-661 (1994).
9. KROESEN, B.J., TER HAAR, A., SPAKMAN, H., WILLEMSE, P., SLEIJFER, D.T., DE VRIES, E.G.E., MULDER, N.H., BERENDSEN, H.H., LIMBURG, P.C., THE, T.H. and DE LEU, L., Local anti-tumor treatment in carcinoma patients with bi-specific-monodonal-amihody-redirected T cells. Cancer Immunol. Immunother., 37, 400-407 (1993).
10. LAMERS, C.H.J., GRATAMA, J.W., WARNAAR, S.O., STOTER, G. and BOLHUIS, R.L.H., Inhibition of bi-specific-monoclonal antibody (bs-Ab)-targeted cytolysis by human anti-mouse antibodies in ovarian-carcinoma patients treated with bs-Ab-targeted activated T lymphocytes. Int. J. Cancer, 60, 450-457 (1995).
11. LAMERS, C.H.J., VAN DE GRIEND, R.J., BRAAKMAN, E., RONTELTAP, C.P.M., BÉNARD, J., STOTER, G., GRATAMA, J.W. and BOLHUIS, R.L.H., Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bi-specific-antibody-directed cellular immunotherapy. Int. J. Cancer, 51, 973-979 (1992).
12. MEZZANZANICA, D., CANEVARI, S., MÉNARD, S., PUPA, S.M., TAGLIABUE, E., LANZAVECCIA, A. and COLNAGHI, M.I., Human ovarian-carcinoma lysis by cytotoxic T cells targeted by bi-specific monoclonal antibodies: analysis of the antibody components. Int. J. Cancer, 41, 609-615 (1988).
13. MIOTTI, S., CANEVARI, S., MÉNARD, S., MEZZANZANICA, D., PORRO, G., PUPA, S.M., REGAZZONI, M., TAGLIABUE, E. and COLNAGHI, M.I., Characterization of human ovarian-carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int. J. Cancer, 39, 297-303 (1987).
14. NITTA, T., SATO, K., YAGITA, H., OKUMURA, K. and ISHII, S., Preliminary trial of specific targeting therapy against malignant glioma. Lancet, 335, 368-371 (1990).
15. PUPA, S.M., CANEVARI, S., FONTANELLI, R., MÉNARD, S., MEZZANZANICA, D., LANZAVECCHIA, A. and COLNAGHI, M.I. Activation of mononuclear cells to be used for hybrid-monoclonal-antibody-induced lysis of human ovariancarcinoma cells. Int. J. Cancer, 42, 455-459 (1988).
16. RENNER, C., JUNG, W., SAHIN, U., DENFELD, R., POHL, C., TRÜMPER, L., HARTMANN, F., DIEHL, V., VAN LIER, R. and PFRKUNDSCHUH, M., Cure of xenografled human tumors by hi-specific monoclonal antibodies and human T cells. Science, 264, 833-835 (1994).
17. STEIS, R.G. and 13 OTHERS, Intraperitoneal-lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J. din. Oncol., 8, 1618-1629 (1990).
18. 2 in ovarian-carcinoma patients. Int. J. Cancer, 66, 477-183 (1996).
19. VAN DUK, J., WARNAAR, S.O., VAN EENDENBURG, J.D.H., THIENPONT, M., BRAAKMAN, E., BOOT, J.H.A., FLEUREN, G.J. and BOLHUIS, R.L.H., Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen. Int. J. Cancer, 43, 344-349 (1989).
20. VAN RAVENSWAAY CLAASEN, H.H., VAN DE GRIEND, R.J., MEZZANZANICA, D., BOLHUIS, R.L.H., WARNAAR, S.O. and FLEUREN, G.J., Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3. Int. J. Cancer, 55, 128-136 (1993).
21. 2 from murine trioma OC/TR with specificity for CD3 and ovarian cancer. Hybridoma, 13, 519-526 (1994).